TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03190252

Intervention type: OTHER
Intervention: Exposure to ambient pressure of maximum 11 ATA
Description: Open sea diving to a maximum depth of 100 msw while breathing Trimix.
Study: NCT03150706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study.
Study: NCT00940719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
Study: NCT00734968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
Study: NCT02843945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Brachytherapy Source Implant
Description: The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
Study: NCT04370041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dokimos Plus aortic valve
Description: Dokimos Plus aortic valve
Study: NCT04296552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary lowFODMAP intervention
Description: Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
Study: NCT03948373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
Study: NCT01992731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Follitropine Bèta

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Follitropine Bèta
Study: NCT04302311

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Holter monitoring
Description: Use of smart device application and technologies to assess for arrhythmias

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Holter monitoring
Description: Use of smart device application and technologies to assess for arrhythmias

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kardia/AliveCor monitoring
Description: Kardia/AliveCor monitoring
Study: NCT03210909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: BMS-986231
Study: NCT00883896

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: Placebo SC administration every 2 weeks X 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2: Placebo SC administration every 2 weeks X 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
Study: NCT02419443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study: NCT04501380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEMCOLO (Rifamycin SV MMX)
Description: Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEMCOLO (Rifamycin SV MMX)
Description: Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
Study: NCT00517166

Intervention type: DEVICE
Intervention: CAT (Combat Arms Tourniquet)
Description: device
Study: NCT02438787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 45 mg
Description: Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 90 mg
Description: Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
Study: NCT01062230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles.
Study: NCT00323934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: Oral dosage 2 times weekly.
Study: NCT00142428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Study: NCT01385839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hair transplantation
Description: Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypodermic needle irritation
Description: In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
Study: NCT04357431

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
Study: NCT02107716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine injection with bicarbonate
Description: bicarbonate added to change pH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lidocaine injection
Description: Lidocaine injection with pH unchanged
Study: NCT00003524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03249259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Study: NCT00439920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose anthracycline
Study: NCT04295629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia
Description: The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia
Description: The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal nerve block
Description: Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal nerve block
Description: Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
Study: NCT03466216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlphaMedix
Description: There is only a single treatment intervention.
Study: NCT02513680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Laser + Amber LED
Description: This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
Study: NCT00734968

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
Study: NCT01174693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
Study: NCT01662778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 microns at 50mg
Description: STAG generated monodisperse 1.5micron particles
Study: NCT02513680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amber LED
Description: This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
Study: NCT04027127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: netrin-1 value on admission to hospital
Study: NCT01662778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 microns at 50mg
Description: STAG generated monodisperse 6 micron particles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: No drug just solvent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI FP
Study: NCT03877679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcenolone +napolycarboxylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric paste
Description: Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
Study: NCT01254773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Bapineuzumab
Description: Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
Study: NCT04207060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy for Pancreatic Function Testing
Description: All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy for Pancreatic Function Testing
Description: All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
Study: NCT01254773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Bapineuzumab
Description: Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Bapineuzumab
Description: Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
Study: NCT03157479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous anesthetic
Description: Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
Study: NCT02082704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SE Game on DSME
Description: Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SE Game on American History
Description: Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
Study: NCT02627989

Intervention type: DRUG
Intervention: Diflucortolone valerate (Nerisona)
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids

Intervention type: DRUG
Intervention: Diflucortolone valerate (Texmeten)
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Study: NCT00544336

Intervention type: OTHER
Intervention: questionnaire administration
Description: no intervention

Intervention type: OTHER
Intervention: survey administration
Description: no intervention

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: no intervention
Study: NCT00896025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours
Study: NCT04658043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention on socioemotional functioning
Description: A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents